Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy

Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy

Abstract Advances in pharmacomicrobiomics have shed light on the pathophysiology of drug‐induced enteropathy associated with the therapeutic use of certain non‐steroidal anti‐inflammatory drugs, anticancer chemotherapies and immunosuppressants. The toxicity pathway results from the post‐glucuronidat...

Full description

Bibliographic Details
Main Authors: Manon Jardou, Clarisse Brossier, Kenza Guiyedi, Quentin Faucher, Roland Lawson
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Pharmacology Research & Perspectives
Subjects:
bacterial β‐glucuronidase
drug‐induced enteropathy
gut microbiome
intestinal dysbiosis
pharmacomicrobiomics
recombinant probiotic
Online Access:https://doi.org/10.1002/prp2.998

Internet

https://doi.org/10.1002/prp2.998

Similar Items